Photobiomodulation Therapy Delays Dry AMD Progression

Multiwavelength PBM approach shows visual acuity and disease morphology benefits.

By: Samuel Asanad, MD, David S. Boyer, MD

Retinal Physician March 1, 2025 Vol 22, Issue March 2025 Page(s): 8-11

5 Key Takeaways

1

Photobiomodulation (PBM) therapy shows promise in delaying the progression of dry age-related macular degeneration (AMD).
2

The FDA approved LumiThera’s Valeda Light Delivery System as the first treatment for vision loss in dry AMD patients in November 2024.
3

PBM utilizes specific wavelengths of light to stimulate cellular responses and enhance mitochondrial function, potentially improving retinal health.
4

Clinical trials indicate that PBM can reduce macular drusen volume and improve visual acuity in patients with intermediate dry AMD.
5

PBM therapy targets mitochondrial dysfunction and inflammation, addressing key pathological features associated with dry AMD.

Samuel Asanad

Specialties: Ophthalmology

Bio: Samuel Asanad, MD, writes on retinal disease, including dry age-related macular degeneration. His work in Retinal Physician has addressed photobiomodulation therapy as a noninvasive approach for delaying progression of dry AMD and evaluating associated visual acuity and disease morphology outcomes.

PentaVision

Retinal Physician

Photobiomodulation Therapy Delays Dry AMD Progression

5 Key Takeaways

1

2

3

4

5

Recommendations